| 17.42 -7.19 (-29.22%) | 05-06 13:51 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 27.77 |
1-year : | 32.33 |
| Resists | First : | 23.77 |
Second : | 27.68 |
| Pivot price | 24.56 |
|||
| Supports | First : | 17.46 |
Second : | 14.53 |
| MAs | MA(5) : | 23.3 |
MA(20) : | 24.29 |
| MA(100) : | 29.05 |
MA(250) : | 30.1 |
|
| MACD | MACD : | -0.3 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 23.8 |
D(3) : | 35.6 |
| RSI | RSI(14): 30.5 |
|||
| 52-week | High : | 41.72 | Low : | 17.46 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AZTA ] has closed below the lower bollinger band by 33.2%. Bollinger Bands are 12.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.37 - 25.49 | 25.49 - 25.6 |
| Low: | 23.66 - 23.79 | 23.79 - 23.92 |
| Close: | 24.39 - 24.6 | 24.6 - 24.8 |
Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.
Tue, 05 May 2026
Earnings Flash (AZTA) Azenta, Inc. Reports Q2 Revenue $145.0M, vs. FactSet Est of $148.5M - marketscreener.com
Tue, 05 May 2026
Azenta (NASDAQ: AZTA) trims 2026 guidance after big Q2 impairment - Stock Titan
Tue, 05 May 2026
Azenta (AZTA) Reports Earnings Tomorrow: What To Expect - StockStory
Tue, 05 May 2026
MSN Money - MSN
Mon, 04 May 2026
Azenta Q2 2026 Earnings Preview — Street Expects $0.14 EPS - AlphaStreet
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 46 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 113.8 (%) |
| Shares Short | 5,520 (K) |
| Shares Short P.Month | 4,810 (K) |
| EPS | 0.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 37.25 |
| Profit Margin | -10.2 % |
| Operating Margin | -4.1 % |
| Return on Assets (ttm) | -0.6 % |
| Return on Equity (ttm) | 1.5 % |
| Qtrly Rev. Growth | 0.8 % |
| Gross Profit (p.s.) | 5.75 |
| Sales Per Share | 12.91 |
| EBITDA (p.s.) | 0.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 63 (M) |
| Levered Free Cash Flow | 109 (M) |
| PE Ratio | 31.18 |
| PEG Ratio | 0.5 |
| Price to Book value | 0.48 |
| Price to Sales | 1.39 |
| Price to Cash Flow | 13.17 |
| Dividend | 0.1 |
| Forward Dividend | 0 |
| Dividend Yield | 0.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|